News & Events

Learn about what's new with CMC Biologics

CMC Biologics and IDT Biologika Announce a Strategic Collaboration to Manufacture Antibody Drug Conjugates


Will Provide an Efficient End-to-End Solution for Development and Manufacture of ADCs

COPENHAGEN, Denmark and DESSAU, Germany, February 17, 2016. CMC Biologics A/S, a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika GmbH, a privately-held life-science company with a 95 year history of expertise in research, development and manufacture of biologics for human and animal health, announced the formation of a strategic collaboration to provide a complete and efficient solution for the manufacture of antibody drug conjugates (ADCs).  

Follow Us
Join us on LinkedIn Follow us on Twitter